Shorla Oncology vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Shorla Oncology is a specialty pharma focused on oncology and rare/pediatric cancers; reformulates approved therapies to address drug shortages; raised $27M Series A in 2022; markets FDA-approved Enrylaze (asparaginase) in the US and EU.
About
Shorla Oncology is a specialty pharmaceutical company co-founded by Sharon Cunningham and Orlaith Ryan in 2019, headquartered in Cork, Ireland, with US operations in Westwood, Massachusetts. The company focuses on developing and commercializing oncology and rare disease drugs, with a particular emphasis on orphan and pediatric indications where treatment options are severely limited or where drug shortages threaten continuity of care. Shorla's approach centers on reformulating proven active pharmaceutical ingredients to improve administration, reduce toxicity, and ensure supply reliability for vulnerable patient populations.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.